[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"palmitoylethanolamide\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:palmitoylethanolamide":29},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,42],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":31,"lastUpdatePostDateStruct":32,"startDateStruct":35,"completionDateStruct":37,"leadSponsor":39,"locationsCount":4},"100621960","beneficial-effects-of-supplementation-with-cronilief-palmitoylethanolamide-phospholipids-in-diabetic-subjects-with-neuropathic-pain-100621960",false,"NCT07377409","Beneficial Effects of Supplementation With CRONILIEF™ (Palmitoylethanolamide Phospholipids) in Diabetic Subjects With Neuropathic Pain.","Randomised, Placebo-controlled Study to Evaluate the Beneficial Effects of Supplementation With CRONILIEF™ (Palmitoylethanolamide Phospholipids), in Addition to Standard Therapy, in Diabetic Subjects With Neuropathic Pain.","Inclusion Criteria:\n\n* Satisfactory metabolic compensation;\n* Presence of moderate symptoms of painful diabetic neuropathy as assessed by the LANSS questionnaire (score ≥12);\n* Taking antidiabetic drugs except insulin;\n* Subjects willing and able to comply with scheduled study visits, the treatment plan, and all procedures outlined in the study.\n\nExclusion Criteria:\n\n* Previous intolerance to a component of the nutraceuticals tested;\n* Individuals with type I diabetes;\n* Uncontrolled diabetes, severe cardiovascular and cerebrovascular diseases;\n* Severe neuropathic symptoms as indicated by the LANSS score;\n* Individuals undergoing insulin treatment;\n* Peripheral neuropathy due to diseases other than diabetes mellitus;\n* History of malignant neoplasm in the 5 years prior to enrolment in the study;\n* Serious neurological, psychological or psychiatric disorders;\n* Clinical signs or history of significant impairment of hepatic or renal function, peptic ulcer or coagulation disorders;\n* Any clinically relevant or unstable disease (e.g., active malignancies, immune system disorders) whose sequelae or treatments could contraindicate participation in the study or interfere with the study's evaluation parameters, in the investigator's judgement; Any disease that could significantly affect the study's outcome, including, but not limited to, chronic medical conditions, psychological disorders, or substance abuse;\n* Alcohol or drug abuse;\n* Women of childbearing age who do not use established contraceptive methods;\n* Pregnancy and breastfeeding.","ALL","18 Years","65 Years",{"count":20,"type":21},70,"ESTIMATED","INTERVENTIONAL",[24],"NA","This study aims to evaluate the potential benefit of an oral nutritional supplement based on CRONILIEF™ (Palmitoylethanolamide Phospholipids) in diabetic subjects with neuropathic pain, compared to a placebo.",[27,28,29],"Neuropathic Pain Management","Diabetic Neuropathies, Painful","Palmitoylethanolamide","NOT_YET_RECRUITING","2026-02-12",{"date":33,"type":34},"2026-02-17","ACTUAL",{"date":36,"type":21},"2026-09-15",{"date":38,"type":21},"2027-01-15",{"name":40,"class":41},"Azienda di Servizi alla Persona di Pavia","OTHER",{"id":43,"slug":44,"hasResults":11,"nctId":45,"briefTitle":46,"officialTitle":47,"acronym":4,"eligibilityCriteria":48,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":49,"targetDuration":4,"studyType":22,"phases":51,"briefSummary":52,"conditions":53,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":55,"lastUpdatePostDateStruct":56,"startDateStruct":58,"completionDateStruct":60,"leadSponsor":62,"locationsCount":64},"100617287","palmitoylethanolamide-vs-ibuprofen-for-pain-after-eswl-100617287","NCT07316660","Palmitoylethanolamide vs Ibuprofen for Pain After ESWL","Palmitoylethanolamide Versus Ibuprofen for Acute Postoperative Pain After Extracorporeal Shock Wave Lithotripsy: A Randomized Trial","Inclusion Criteria:\n\n* Age 18-65 years\n* ASA I or II\n* Undergoing elective ESWL for renal or upper ureteric calculi\n* Expected discharge same day or within 24 hours (outpatient ESWL).\n* Able to provide informed consent and comply with study procedures (including diary\u002FVAS recordings).\n* Not currently taking chronic NSAIDs, opioids, or PEA supplements for ≥7 days prior to ESWL.\n\nExclusion Criteria:\n\n* Chronic pain or daily analgesic use.\n* Known allergy or contraindication to PEA, ibuprofen.\n* Active peptic ulcer disease, known bleeding disorder, anticoagulant therapy\n* Pregnancy or lactation.\n* Use of steroids or other pain-modulating drugs.\n* Severe renal impairment (eGFR \\\u003C30 mL\u002Fmin\u002F1.73 m²).\n* Hepatic failure or significant liver enzyme elevation (AST\u002FALT \\>3× ULN).",{"count":50,"type":21},120,[24],"Pain after extracorporeal shock wave lithotripsy (ESWL), a non-surgical procedure used to treat kidney stones, is common and is usually treated with non-steroidal anti-inflammatory drugs (NSAIDs) such as ibuprofen. However, NSAIDs may cause side effects in some patients, including stomach irritation and kidney problems.\n\nPalmitoylethanolamide (PEA) is a naturally occurring substance in the body with anti-inflammatory and pain-relieving properties and has been shown to be safe in previous studies. This study aims to compare the effectiveness of PEA with ibuprofen for controlling acute postoperative pain after ESWL.\n\nParticipants undergoing ESWL will be randomly assigned to receive either oral PEA or oral ibuprofen. Pain intensity will be measured using a visual analogue scale during the first 24 hours after the procedure. The use of rescue pain medication and any side effects will also be recorded.\n\nThe results of this study may help determine whether PEA can be an effective alternative to ibuprofen for the management of acute pain after ESWL.",[54,29],"Pain After Extracorporeal Shock Wave Lithotripsy","2025-12-19",{"date":57,"type":34},"2026-01-05",{"date":59,"type":21},"2026-01-01",{"date":61,"type":21},"2026-07-01",{"name":63,"class":41},"Benha University",1]